Greifswald, January, 2024
The CHEPLAPHARM Group acquires the commercial rights in Europe for Myocet® from Teva, thereby expanding its portfolio in the field of oncology. The medication is used for the first-line treatment of metastatic breast cancer in adult women. Myocet® is the first product that CHEPLAPHARM acquires from Teva.
Myocet® is a non-pegylated, liposomal encapsulated formulation of doxorubicin hydrochloride that has been marketed in the European Union for more than 20 years. In combination with cyclophosphamide Myocet® is indicated for the first-line treatment of metastatic breast cancer in women, one of the most common cancers worldwide. According to the WHO Global Cancer Observatory, over 500,000 women in Europe were diagnosed with breast cancer in 2020. Anthracycline-based chemotherapy, such as doxorubicin, is one of the most effective treatments for breast cancer.
"Myocet® is the first product we are acquiring from Teva and we are now working closely together on an efficient and smooth integration," says Edeltraud Lafer, CEO of CHEPLAPHARM Arzneimittel GmbH. "The treatment fits into our existing oncology branch of our highly diversified product portfolio."
As a leading acquirer of originator products from research-based pharmaceutical companies, CHEPLAPHARM has built up a globally functioning structure for the commercialisation of well-established drugs over the past 20 years, into which Myocet® will now be integrated following the acquisition. With this transaction, which includes the rights for the European markets of Myocet®, CHEPLAPHARM strengthens its existing oncology portfolio. The transaction includes product registrations, trademarks and intellectual property.